-
FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma
19 Jun 2025 01:08 GMT
… relapsed or refractory follicular lymphoma.
The effectiveness of … or refractory marginal zone lymphoma outside of clinical trials … relapsed/refractory follicular lymphoma,” Dr. Laurie H. … relapsed or refractory follicular lymphoma.” Press release. U. …
-
FDA Approves Tafasitamab Combo for R/R Follicular Lymphoma
19 Jun 2025 00:29 GMT
… relapsed/refractory follicular lymphoma,” Laurie H. Sehn, … or refractory marginal zone lymphoma (MZL)—which is … for relapsed or refractory follicular lymphoma. FDA. June 18, … #47;R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND). ClinicalTrials. …
-
FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma
18 Jun 2025 20:24 GMT
… infection; or central nervous system lymphoma involvement.
Patients were randomly assigned … points for patients with follicular lymphoma included complete response (CR) … (R/R) follicular lymphoma or marginal zone lymphoma (InMIND). ClinicalTrials.gov …
-
FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma
18 Jun 2025 20:19 GMT
… with relapsed or refractory follicular lymphoma (FL).
Full prescribing information for … relapsed or refractory marginal zone lymphoma outside of controlled clinical trials …
-
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
18 Jun 2025 20:00 GMT
… neutrophils and decreased lymphocytes.
“Follicular lymphoma is generally an indolent yet … refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including … relapsed or refractory marginal zone lymphoma outside of controlled clinical trials …
-
Lyell reports new clinical data from trial of large B-cell lymphoma therapy
18 Jun 2025 19:30 GMT
… those with large B-cell lymphoma (LBCL) in the third or … patients with large B-cell lymphoma in the third- or later …
-
Innovo’s INNO-220 exerts antitumoral activity against lymphoma cells
18 Jun 2025 19:18 GMT
… about 85% of non-Hodgkin lymphoma cases; therapeutic approaches are represented …
-
VIDEO: New research highlights roles of ctDNA, antibody-drug conjugates in lymphoma
18 Jun 2025 17:07 GMT
… other options for patients with lymphoma, which were presented at ASCO … DNA in patients with aggressive lymphomas, we are seeing efforts to …
-
Researchers Identify Key B-Cell Lymphoma Traits Linked with Greatest Benefit From CD19 CAR T Cell Therapy
18 Jun 2025 15:54 GMT
… patients with LBCL to create “LymphoMAPs” that provide detailed information about … newly diagnosed and previously treated lymphoma patients. In total, researchers profiled … identified three primary types of lymphoma microenvironments in patients with LBCL …
-
VIDEO: Odronextamab shows ‘high efficacy’ in relapsed, refractory follicular lymphoma
17 Jun 2025 22:28 GMT
… with relapsed or refractory follicular lymphoma. Results were presented at ASCO … with relapsed/refractory follicular lymphoma,” Jagadeesh said. “There are ongoing …